PMID- 31116807
OWN - NLM
STAT- MEDLINE
DCOM- 20200203
LR  - 20200203
IS  - 2326-6929 (Electronic)
IS  - 0011-4162 (Linking)
VI  - 103
IP  - 4
DP  - 2019 Apr
TI  - Nivolumab-induced lichen planus pemphigoides.
PG  - 224-226
AB  - Programmed cell death 1 (PD-1) receptor inhibitors, such as nivolumab, are used 
      in the treatment of non-small cell lung cancers, melanoma, and other cancers. 
      Cutaneous adverse events (AEs) associated with anti-PD-1 therapy have been widely 
      documented. Although cutaneous AEs often are mild, some patients can develop 
      notable morbidity. We report an 87-year-old woman with stage IV non-small cell 
      lung cancer who developed a bullous eruption on the trunk and extremities. Biopsy 
      of the lesions revealed a subepidermal bullous lichenoid eruption with positive 
      immunofluorescence in a linear pattern at the basement membrane zone, consistent 
      with lichen planus pemphigoides (LPP). The patient improved with oral prednisone 
      and cessation of nivolumab therapy.
FAU - Strickley, John D
AU  - Strickley JD
AD  - Department of Medicine, University of Louisville School of Medicine, Kentucky, 
      USA.
FAU - Vence, Lacey M
AU  - Vence LM
AD  - Division of Dermatology, University of Louisville School of Medicine, Kentucky, 
      USA.
FAU - Burton, Sonya K
AU  - Burton SK
AD  - Division of Dermatology, University of Louisville School of Medicine, Kentucky, 
      USA.
FAU - Callen, Jeffrey P
AU  - Callen JP
AD  - Division of Dermatology, University of Louisville School of Medicine, Kentucky, 
      USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Immunological/*adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Lichen Planus/chemically induced/*diagnosis/pathology
MH  - Lung Neoplasms/*drug therapy
MH  - Nivolumab/*adverse effects
MH  - Pemphigus/chemically induced/*diagnosis/pathology
EDAT- 2019/05/23 06:00
MHDA- 2020/02/06 06:00
CRDT- 2019/05/23 06:00
PHST- 2019/05/23 06:00 [entrez]
PHST- 2019/05/23 06:00 [pubmed]
PHST- 2020/02/06 06:00 [medline]
PST - ppublish
SO  - Cutis. 2019 Apr;103(4):224-226.